By Fineline Cube 
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising 800 million yuan (≈ US$111 million) co‑led by Shenzhen Capital Group and PICC Capital, with participation from the AstraZeneca‑CICC Healthcare Industry Fund.
Financing Summary & Investor Syndicate
| Round | Amount | Co‑Leads | Strategic Participant |
|---|---|---|---|
| Series D | 800 million yuan | Shenzhen Capital Group, PICC Capital | AstraZeneca‑CICC Healthcare Industry Fund |
Company Profile & Strategic Infrastructure
- Founded: 2016
- Business: R&D, production, and sales of medical isotopes and radiopharmaceuticals
- Flagship Asset: China’s first commercial 30MeV IKON proton accelerator for radionuclide production
- Pipeline Focus: Yttrium‑90 [⁹⁰Y] carbon microsphere injection and radionuclide‑conjugated biological monoclonal antibodies/polypeptides
Technology Platform & Pipeline
| Asset Category | Key Products | Application |
|---|---|---|
| Radioembolics | Yttrium‑90 [⁹⁰Y] carbon microsphere | Hepatocellular carcinoma, liver metastases |
| RDCs | Radionuclide‑conjugated antibodies/peptides | Oncology (multiple solid tumors) |
| Manufacturing | 30MeV IKON proton accelerator | Commercial‑scale isotope production |
Market Context & Investment Thesis
- Radiopharmaceutical Market: China market projected to reach ¥30 billion by 2030, growing at >25 % CAGR
- Vertical Integration: Proton accelerator provides end‑to‑end control from isotope production to radiopharmaceutical manufacturing
- Strategic Validation: AstraZeneca‑CICC participation signals Big Pharma endorsement of China’s radiopharma ecosystem
- Use of Proceeds: Accelerate clinical development, expand RDC pipeline, and scale commercial production capacity
Forward‑Looking Statements
This brief contains forward‑looking statements regarding New Radiomedicine’s development timelines, commercial prospects, and market expansion. Actual results may differ due to regulatory, competitive, and operational uncertainties.-Fineline Info & Tech